Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
作者机构：Department of HematologyThe First Hospital of Jilin UniversityJilin Provincial Hematology Research InstituteNational Key DisciplineChangchun 130021Jilin ProvinceChina Department of PathologyThe First Hospital of Jilin UniversityChangchun 130021Jilin ProvinceChina Department of CardiologyThe Third Hospital of Jilin UniversityChangchunJilin Province 130031China
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2020年第8卷第14期
页 面：3122-3129页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：a grant from the Department of Finance of Jilin Province No.2018SCZWSZX-031
主 题：Hepatosplenic T-cell lymphoma Gamma-delta T-cell lymphoma Chidamide Novel agent Case report
摘 要：BACKGROUND Hepatosplenic T-cell lymphoma(HSTCL)is a rare subtype of non-Hodgkin’s lymphoma,which has an aggressive clinical course and an extremely poor *** is a novel,orally active,benzamide-type histone deacetylase(HDAC)inhibitor that has been used for peripheral T-cell lymphoma(PTCL)***,to date,there has been no report of the treatment and effect of the HDAC inhibitor chidamide in HSTCL,which is a special subtype of *** SUMMARY A 45-year-old male patient was admitted with splenomegaly and slight *** was diagnosed with HSTCL via *** patient was treated with fractionated cyclophosphamide,vincristine,doxorubicin,and dexamethasone alternating with high-dose methotrexate and cytarabine regiment as inductive ***,the disease progressed rapidly during chemotherapy before a suitable allogeneic gene transplant donor was *** chidamide-combined chemotherapy regimen and single-drug oral maintenance regimen achieved complete remission,duration of response of 9 mo,and overall survival of 15 *** The novel agent chidamide can be used in HSTCL to achieve deep remission and improve the duration of response and overall survival.
维普期刊数据库